01
2020-09
New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base
On 28 August 2020, 真人直营投注网站 (Stock Code: 9939.HK, hereinafter referred to as the “Kintor Pharmaceutical”), officially moved to Suzhou self-established R&D center and industrialization base, symbolising a new development chapter for Kintor Pharmaceutical.
24
2020-08
First Patient Enrolment for the COVID-19 Clinical Trial of Proxalutamide Completed
(August 24, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) , declared that the Clinical Trial (identifier: NCT04446429) to conduct research for Proxalutamide (GT0918) as a treatment for the coronavirus disease (“COVID-19”)has recorded the first patient enrolment in Brazil. The Company plans to enrol a total of 381 subjects and it’s expected that the enrolment will be completed in 2 months.
23
2020-08
真人直营投注网站 Announces 2020 Interim Results
(August 23, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939.HK, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other indications. The Company was pleased to announce its recent business highlights and the financial results for the six months ended 30 June 2020 (the “Reporting Period”).
21
2020-08
(August 21, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical”) announced that Kintor Pharmaceutical and Gensun Biopharma Inc., (a holding subsidiary of Zelgen Biopharmaceuticals Co., Ltd. (stock code:688266.SH), hereinafter referred to as “Gensun”) signed an exclusive license agreement to promote the clinical development and commercialization of Gensun’s PD-L1/TGF-βdual-targeting antibody GS19 in Greater China (including the Chinese mainland, Hong Kong, Macau and Taiwan).
04
2020-08
Results of Kintor's Phase Ib Clinical Trials of Pyrilutamide in America
真人直营投注网站 (stock code: 9939.HK, hereinafter referred to as "Kintor" or the "Company") announced that the phase Ib clinical trials of Pyrilutamide (KX-826) against androgenetic alopecia were completed in the United States. All subjects exited the trials. Data analysis, cleaning and summarisation are underway.
30
2020-07
真人直营投注网站 (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced that the Company has entered a partnership agreement with Alphamab Oncology (stock code: 9966.HK), to jointly develop the combination therapy of ALK-1 monoclonal antibody GT90001 and PD-L1 / CTLA-4 bispecific antibody KN046 in hepatocellular carcinoma (HCC).
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn